An in Vitro Model for Cytogenetic Conversion in CML. Interferon-alpha Preferentially Inhibits the Outgrowth of Malignant Stem Cells Preserved in Long-term Culture

Overview

Journal J Clin Invest

Specialty General Medicine

Date 1998 Sep 3

PMID 9727066

Citations 3

Authors

J J Cornelissen

R E Ploemacher

B W Wognum

A Borsboom

H C Kluin-Nelemans

A Hagemeijer

B Lowenberg

Affiliations

Soon will be listed here.

Abstract

IFN-alpha has been shown to prolong survival in chronic myeloid leukemia patients, but its mechanism of action is still not understood. The human cobblestone area-forming cell (CAFC) assay allows for the measurement of the concentration of normal as well as malignant stem cells, while their progeny can be measured in parallel long-term culture (LTC) in flasks. Using CAFC and LTC assays, we have examined direct effects of IFN-alpha (500; 5,000 IU/ml) on the maintenance and outgrowth of CD34-enriched normal and malignant stem cells, obtained from six patients with an established major cytogenetic response to IFN-alpha and from four nonresponding patients. CAFC concentrations were not affected by IFN-alpha. In contrast, IFN-alpha strongly inhibited the clonogenic output in flask LTC. Nucleated cells (NC) produced in LTC were evaluated by fluorescent in situ hybridization (FISH) for the presence of the Philadelphia (Ph) translocation. After 8 wk of LTC, the percentage of Ph+ NCs produced was significantly more inhibited by IFN-alpha in responding patients than in nonresponders. Control LTC without IFN-alpha showed no significant differences of Ph+ NC production between responders and nonresponders. These findings provide the first in vitro model for cytogenetic conversion and suggest that direct antiproliferative effects of IFN-alpha account for the cytogenetic response observed clinically.

Citing Articles

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Geelen I, Gullaksen S, Ilander M, Olssen-Stromberg U, Mustjoki S, Richter J Ann Hematol. 2023; 102(6):1395-1408.

PMID: 37119314 DOI: 10.1007/s00277-023-05199-1.

New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.

Westerweel P, Te Boekhorst P, Levin M, Cornelissen J Front Oncol. 2019; 9:665.

PMID: 31448223 PMC: 6691769. DOI: 10.3389/fonc.2019.00665.

PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.

Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K PLoS One. 2010; 5(7):e11770.

PMID: 20668669 PMC: 2909896. DOI: 10.1371/journal.pone.0011770.

References

Agarwal R, Doren S, Hicks B, Dunbar C . Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood. 1995; 85(5):1306-12. View

Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett A, Rotoli B . Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 1997; 89(3):957-64. View

Fialkow P, Jacobson R, Papayannopoulou T . Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977; 63(1):125-30. DOI: 10.1016/0002-9343(77)90124-3. View

Talpaz M, McCredie K, Mavligit G, Gutterman J . Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood. 1983; 62(3):689-92. View

Groffen J, Stephenson J, Heisterkamp N, de Klein A, Bartram C, Grosveld G . Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984; 36(1):93-9. DOI: 10.1016/0092-8674(84)90077-1. View

Einat M, Resnitzky D, Kimchi A . Close link between reduction of c-myc expression by interferon and, G0/G1 arrest. Nature. 1985; 313(6003):597-600. DOI: 10.1038/313597a0. View

Talpaz M, Kantarjian H, McCredie K, Trujillo J, Keating M, Gutterman J . Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986; 314(17):1065-9. DOI: 10.1056/NEJM198604243141701. View

Eaves A, Cashman J, Gaboury L, Kalousek D, Eaves C . Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci U S A. 1986; 83(14):5306-10. PMC: 323940. DOI: 10.1073/pnas.83.14.5306. View

Berenson R, Andrews R, Bensinger W, Kalamasz D, Knitter G, Buckner C . Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest. 1988; 81(3):951-5. PMC: 442551. DOI: 10.1172/JCI113409. View

10.

Kimchi A, Resnitzky D, Ber R, GAT G . Recessive genetic deregulation abrogates c-myc suppression by interferon and is implicated in oncogenesis. Mol Cell Biol. 1988; 8(7):2828-36. PMC: 363502. DOI: 10.1128/mcb.8.7.2828-2836.1988. View

11.

Carlo-Stella C, Cazzola M, Ganser A, Bergamaschi G, Pedrazzoli P, Hoelzer D . Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). Blood. 1988; 72(4):1293-9. View

12.

Ploemacher R, van der Sluijs J, Voerman J, Brons N . An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood. 1989; 74(8):2755-63. View

13.

Galvani D, Cawley J . Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br J Haematol. 1989; 73(4):475-9. DOI: 10.1111/j.1365-2141.1989.tb00283.x. View

14.

Sutherland H, Lansdorp P, Henkelman D, Eaves A, Eaves C . Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci U S A. 1990; 87(9):3584-8. PMC: 53946. DOI: 10.1073/pnas.87.9.3584. View

15.

Arnoldus E, Wiegant J, Noordermeer I, Wessels J, Beverstock G, Grosveld G . Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet Cell Genet. 1990; 54(3-4):108-11. DOI: 10.1159/000132972. View

16.

Dowding C, Guo A, Osterholz J, Siczkowski M, Goldman J, Gordon M . Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood. 1991; 78(2):499-505. View

17.

Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D . Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood. 1991; 78(6):1476-84. View

18.

Upadhyaya G, Guba S, Sih S, Feinberg A, Talpaz M, Kantarjian H . Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest. 1991; 88(6):2131-6. PMC: 295821. DOI: 10.1172/JCI115543. View

19.

Resnitzky D, Tiefenbrun N, Berissi H, Kimchi A . Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc Natl Acad Sci U S A. 1992; 89(1):402-6. PMC: 48245. DOI: 10.1073/pnas.89.1.402. View

20.

Burke L, Bybee A, Thomas N . The retinoblastoma protein is partially phosphorylated during early G1 in cycling cells but not in G1 cells arrested with alpha-interferon. Oncogene. 1992; 7(4):783-8. View